Zydus Lifesciences has launched Anyra, a biosimilar of Regeneron Pharmaceuticals’ Aflibercept 2 mg that is indicated for certain eye diseases.

Zydus Lifesciences is in focus after receiving USFDA clearance with zero observations for its Ahmedabad facility and ...

In this expert perspective from Retina 2026, Murtaza K. Adam, MD, of Colorado Retina Associates, discusses real-world data coming in 2026.He said he is excited about data on Eylea HD (aflibercept 8 mg ...

Real-world data show faricimab allows for treatment interval extension in nAMD patients previously treated with other ...

Rapid drying of retinal fluid with faricimab injections may help identify patients with neovascular age-related macular degeneration who can safely extend time between injections.

The study assessed changes in retinal structure and visual function before and after intravitreal pegcetacoplan initiation. A ...

WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that eight abstracts were accepted for oral presentations at the 49 th Macula Society ...

Zydus introduces biosimilar Aflibercept 2 mg Anyra for advancing ophthalmic care: Our Bureau, Mumbai Thursday, February 19, 2026, 15:45 Hrs [IST] Zydus Lifesciences Ltd., an innov ...

Zydus Lifescience launches Anyra, India's first biosimilar of Aflibercept 2 mg, for retinal care. Q3 results show strong ...

Zydus Lifesciences announced the launch of Anyra, India's first indigenously developed biosimilar of Aflibercept 2 mg. Zydus has also signed an agreement with Regeneron Pharmaceuticals, Inc. and Bayer ...

Zydus Lifesciences announced the launch of Anyra, India's first indigenously developed biosimilar of Aflibercept 2 mg, aimed at treating a range of serious retinal disorders.

In a phase 3 trial, Axpaxli, a tyrosine kinase inhibitor, achieved its superiority primary endpoint vs. aflibercept for the ...